Polymorphic oxidation of debrisoquine in lung cancer patients
- 31 December 1991
- journal article
- Published by Elsevier in European Journal of Cancer and Clinical Oncology
- Vol. 27 (2) , 158-161
- https://doi.org/10.1016/0277-5379(91)90477-u
Abstract
No abstract availableKeywords
This publication has 16 references indexed in Scilit:
- Debrisoquine oxidation phenotype and susceptibility to lung cancer.British Journal of Clinical Pharmacology, 1990
- Debrisoquine metabolism and genetic predisposition to lung cancerBritish Journal of Cancer, 1989
- Xenobiotic and endobiotic inhibitors of cytochrome p-450dbl function, the target of the debrisoouine/sparteine type polymorphismBiochemical Pharmacology, 1988
- Genetically determined polymorphisms in drug oxidationHepatology, 1986
- Metabolic oxidation phenotypes as markers for susceptibility to lung cancerNature, 1984
- Carcinogens, Drugs, and Cytochromes P-450New England Journal of Medicine, 1983
- Some observations on the oxidation phenotype status of Nigerian patients presenting with cancerCancer Letters, 1981
- POLYMORPHIC HYDROXYLATION OF DEBRISOQUINE IN MANThe Lancet, 1977
- Determination of debrisoquine and its 4-hydroxy metabolite in biological fluids by gas chromatography with flame-ionization and nitrogen-selective detectionJournal of Chromatography A, 1977
- Aryl Hydrocarbon Hydroxylase Inducibility and Bronchogenic CarcinomaNew England Journal of Medicine, 1973